Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02135029 · ClinicalTrials.gov registry record · Phase 3
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 184
- Enrollment target
NCT02135029 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 184 participants.
The verdict
NCT02135029, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 184 participants
- Enrollment target
Study Summary
This study is a multicenter, double blinded, active and placebo controlled randomized clinical trial to demonstrate a superior lipid lowering effect of Bococizumab (PF-04950615; RN316) compared to placebo in subjects who are statin intolerant.
Interventions
- DRUG Atorvastatin
- DRUG Bococizumab (PF-04950615;RN316)
- OTHER Placebo for Bococizumab (PF-04950615;RN316)
- OTHER Placebo for atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02135029
The ClinicalTrials.gov registry entry for NCT02135029 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Atorvastatin is the first listed.
NCT02135029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02135029 about?
NCT02135029 is a clinical study titled "Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins". This study is a multicenter, double blinded, active and placebo controlled randomized clinical trial to demonstrate a superior lipid lowering effect of Bococizumab (PF-04950615; RN316) compared to placebo in subjects who are statin intolerant.
What is the current status of trial NCT02135029?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 184 participants. The study started on 2014-06. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02135029?
The interventions under investigation include: Atorvastatin (DRUG), Bococizumab (PF-04950615;RN316) (DRUG), Placebo for Bococizumab (PF-04950615;RN316) (OTHER), Placebo for atorvastatin (OTHER).
Who is sponsoring clinical trial NCT02135029?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.